CervoMed
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 Park Plz Ste 424, Boston, Massachuset...Phone Number
(617) 744-4400Website
www.cervomed.comRevenue
-Stock Symbol
CRVOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About CervoMed
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. Its lead therapeutic program is being investigated for multiple neurological conditions, including disorders that affect cognition, language, and motor function. Through clinical research and strategic development efforts, CervoMed aims to advance disease-modifying treatments that address significant unmet medical needs and improve outcomes for patients living with progressive brain disorders.Explore more
CervoMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CervoMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on CervoMed recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at CervoMed
CervoMed, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CervoMed had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CervoMed has new funding data
Check if CervoMed has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CervoMed launches new products
Check out if CervoMed is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined CervoMed as Masked Content
Find 3 more new buyers
Compare Similar Companies to CervoMed
Compare insights from companies similar to CervoMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CervoMed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CervoMed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CervoMed.
CervoMed financials insights
Gather financial insights about CervoMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$149.4M
2026
Stock/Share Issuance
$10.5M
CervoMed Tech Stack
A closer look at the technologies used by CervoMed
Most Recent Scoops
Project
CervoMed has received an Innovative Licensing and Access Program (ILAP) designation from the UK regulatory authority after submitting placebo-controlled Phase 2b data for neflamapimod in dementia with Lewy bodies in April, representing regulatory validation of the clinical data generated to date.
Clinical Operations
Project
CervoMed has reported that neflamapimod-treated patients in a Phase 2b MRI sub-study conducted in the UK and the Netherlands showed a 3.5% increase in basal forebrain volume during the placebo-controlled period, while placebo patients experienced progressive volume loss, with patients who transitioned to neflamapimod at week 16 subsequently showing stabilization or improvement in basal forebrain volume.
Project
CervoMed has announced that the FDA and MHRA are aligned on key Phase III trial design elements for neflamapimod in dementia with Lewy bodies, including the primary endpoint of CDR sum of boxes and the acceptability of a single Phase III trial to support regulatory approval.
Clinical Operations
Project
CervoMed has reported that its Phase 2b study of neflamapimod in dementia with Lewy bodies demonstrated a 0.7-point improvement in CDR sum of boxes versus placebo in the pure DLB population using lower blood concentration capsules (Batch A), exceeding the 0.5-point threshold considered clinically meaningful, with a P value of 0.054 in 45 to 48 patients.
Medical Research, Pharmaceuticals, Clinical Operations
Project
CervoMed News & Media
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicinesCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conferenceCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CervoMed
Sign Up For FreeTo access detailed company insights
CervoMed is a clinical-stage biotechnology company focused on developing innovative therapies for age-related neurodegenerative and neurological disorders. The companys research is centered on targeting underlying disease mechanisms associated with neuroinflammation and neurodegeneration through the development of novel small-molecule treatments. I... Read More
